CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
|CHONGQING LUMMY PHARMACEUTICAL CO., LTD. Patent applications|
|Patent application number||Title||Published|
|20160106623||DOUBLE-HEADED TRANSFUSION CONTAINER - A double-headed transfusion container comprises a body portion (||04-21-2016|
|20150202120||INTEGRATED MEDICINE MIXING INTERFACE - An integrated medicine mixing interface comprising a medicine mixing mouth (||07-23-2015|
|20150174006||PREASSEMBLED MEDICINE MIXER - A preassembled medicine mixer comprises a rotary sleeve (||06-25-2015|
|20150157536||DOSER HAVING TWO NEEDLES - A doser having two needles. The two needles consist of a needle seat (||06-11-2015|
|20130172283||LYOPHILIZED FORMULATION OF PECTIN-ADRIAMYCIN CONJUGATE AND PREPARATION METHOD THEREOF - The invention belongs to the pharmaceutical field, and particularly relates to a lyophilized formulation of pectin-adriamycin conjugate and a preparation method thereof. In order to solve insolubility problem of the pectin-adriamycin conjugate (hereinafter referred to as PAC), improve bioavailability and facilitate preparation, the inventor prepared the PAC into a nanosuspension. However, as long-term stability of the nanosuspension is poor, the inventor proposed to prepare the nanosuspension into a lyophilized formulation, that is, an insoluble pectin-adriamycin conjugate is prepared into a suspension or nanosuspension, and a lyophilized support agent is added to the suspension for lyophilization treatment to prepare the lyophilized formulation. Lyophilized products prepared from the nanosuspension are characterized by enhanced stability of nano-particle size and enhanced stability of drug loading rate, which provides a new solution for clinical application of the PAC.||07-04-2013|
|20120244193||PASSIVE SOLID TUMOR TARGETING ANTICANCER PRODRUG AND PREPARATION METHOD THEREOF - The invention relates to a passive solid tumor-targeted anticancer prodrug and a preparation method thereof, belonging to the field of antitumor drugs. The preparation method includes the following steps: reacting low molecular weight pectin with Mw of 5,000-45,000 with doxorubicin to obtain a pectin-doxorubicin conjugate with Mw of 100,000-1,000,000, preparing the conjugate into a suspension, and treating the suspension in an ultra-high pressure nano homogenizer to obtain the passive solid tumor-targeted anticancer prodrug with particle size of 100 nm-200 nm and melting point of 220-245°, wherein the pectin and doxorubicin are linked by an amide bond, and the pectin is linked by an ester bond formed by condensing carboxyl groups and hydroxyl groups of pectin molecules. Cell inhibition rate of the anticancer prodrug for humanized lung cancer cells NCI-H446 and A549 is equivalent to that of doxorubicin hydrochloride. In the efficacy research of melanoma B16 pulmonary metastasis model mice, the life span of tumor-bearing mice is 42.3±12.4 days, which is remarkably higher than that of the doxorubicin hydrochloride group (23.1±10.2 days).||09-27-2012|
Patent applications by CHONGQING LUMMY PHARMACEUTICAL CO., LTD.